<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857571</url>
  </required_header>
  <id_info>
    <org_study_id>B0461003</org_study_id>
    <nct_id>NCT00857571</nct_id>
  </id_info>
  <brief_title>A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.</brief_title>
  <official_title>An Open-Label Randomized Incomplete Block Four-Way Crossover Study To Evaluate The Dose Response Of PF-02413873 Tablets And PF-02413873 Suspension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares the plasma concentrations of PF-02413873 after administration of several
      doses as suspension and as tablets
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Cmax, AUCinf</measure>
    <time_frame>June - July 2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax, Tlag, AUClast, AUCt, tÂ½, Frel.</measure>
    <time_frame>June-July 2009</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-02413873 suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-02413873 Phase 2 Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150 mg Suspension</intervention_name>
    <description>Single oral dose of 150 mg of PF-02413873 suspension</description>
    <arm_group_label>Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg Suspension</intervention_name>
    <description>Single oral dose of 30 mg of PF-02413873 suspension</description>
    <arm_group_label>Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 mg Suspension</intervention_name>
    <description>Single oral dose of 400 mg of PF-02413873 suspension</description>
    <arm_group_label>Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Suspension</intervention_name>
    <description>Single oral dose of 5 mg of PF-02413873 suspension</description>
    <arm_group_label>Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>750 mg Suspension</intervention_name>
    <description>Single oral dose of 750 mg of PF-02413873 suspension</description>
    <arm_group_label>Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>150 mg Tablet</intervention_name>
    <description>Single oral dose of 150 mg of PF-02413873 tablets</description>
    <arm_group_label>Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mg Tablet</intervention_name>
    <description>Single oral dose of 30 mg of PF-02413873 tablets</description>
    <arm_group_label>Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 mg Tablet</intervention_name>
    <description>Single oral dose of 400 mg of PF-02413873 tablets</description>
    <arm_group_label>Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Tablet</intervention_name>
    <description>Single oral dose of 5 mg of PF-02413873 tablets</description>
    <arm_group_label>Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>750 mg Tablet</intervention_name>
    <description>Single oral dose of 750 mg of PF-02413873 tablets</description>
    <arm_group_label>Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers.

          -  Female volunteers have to be of non-childbearing potential

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Any condition possibly affecting drug absorption (eg, gastrectomy).

          -  A positive urine drug screen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0461003&amp;StudyName=A%20Four-Way%20Cross-Over%20Study%20To%20Compare%20The%20Plasma%20Concentrations%20Of%20PF-02413873%20After%20Oral%20Administration%20Of%20Several%20Doses%20As%20Suspension</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <last_update_submitted>October 22, 2010</last_update_submitted>
  <last_update_submitted_qc>October 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Dose Response Bioavailability Study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

